Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU)
-
- Randall Severance
- Synexus Clinical Research, Chandler, AZ, USA
-
- Howard Schwartz
- Research Centers of America, Hollywood, FL, USA
-
- Ron Dagan
- Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel
-
- Laurie Connor
- Merck & Co., Inc., Kenilworth, NJ, USA
-
- Jianing Li
- Merck & Co., Inc., Kenilworth, NJ, USA
-
- Alison Pedley
- Merck & Co., Inc., Kenilworth, NJ, USA
-
- Jonathan Hartzel
- Merck & Co., Inc., Kenilworth, NJ, USA
-
- Tina M. Sterling
- Merck & Co., Inc., Kenilworth, NJ, USA
-
- Katrina M. Nolan
- Merck & Co., Inc., Kenilworth, NJ, USA
-
- Gretchen M. Tamms
- Merck & Co., Inc., Kenilworth, NJ, USA
-
- Luwy K. Musey
- Merck & Co., Inc., Kenilworth, NJ, USA
-
- Ulrike K. Buchwald
- Merck & Co., Inc., Kenilworth, NJ, USA
収録刊行物
-
- Human Vaccines & Immunotherapeutics
-
Human Vaccines & Immunotherapeutics 18 (1), 1-14, 2021-11-02
Informa UK Limited
